Deuterium Capital Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-1,500
Closed -$269K 101
2022
Q4
$269K Buy
+1,500
New +$245K 0.71% 41

Other funds holding MRNA

Deuterium Capital Management's MRNA Position: Q1 2023 in Review

Deuterium Capital Management sold out of Moderna (MRNA) in Q1 2023, closing a stake of 1,500 shares — an estimated $269K sold.

Deuterium Capital Management first reported a position in MRNA in Q4 2022 and held it in 1 quarter. The position peaked at $269K in Q4 2022. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Deuterium Capital Management reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • Deuterium Capital Management sold 1,500 Moderna shares in Q1 2023, an estimated $269K.
  • Deuterium Capital Management first reported a position in Moderna in Q4 2022 and held it in 1 quarter.
  • Deuterium Capital Management's Moderna position peaked at $269K in Q4 2022.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Deuterium Capital Management's 13F filing for Q1 2023, filed 12 May 2023.